Guggenheim Initiates Coverage On InMed Pharmaceuticals with Buy Rating, Announces Price Target of $42
Benzinga Newsdesk 20 hours ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Seamus Fernandez initiates coverage on InMed Pharmaceuticals (NASDAQ:INM) with a Buy rating and announces Price Target of $42.
Guggenheim analyst Seamus Fernandez initiates coverage on InMed Pharmaceuticals (NASDAQ:INM) with a Buy rating and announces Price Target of $42.